At a glance
ClinicalIndex Comparison RecordN/ACompleted· 206 enrolled
Drug / intervention
Ice-Sense3TM/ ProSenseTMdevice
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Cryoablation of Low Risk Breast Cancer Less Than 1.5 cm: An Evaluation of Local Recurrence (Ice3 Trial)
In Brief
A clinical study evaluating Ice-Sense3TM/ ProSenseTM for Breast Cancer. Completed, enrolled 206 participants across 19 sites.
Detailed Summary
To evaluate the efficacy of cryoablation without lumpectomy and its impact on local and distant recurrence of early stage breast cancer .
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsBreast Cancer
CountriesUnited States
Collaborators--
Timeline
N/ACompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 2014
Enrollment StartOct 2014
Primary CompletionMar 2024
Study CompletionMay 2024
TodayJul 2026
First PostedJul 25, 2014
Enrollment StartOct 1, 2014
Primary CompletionMar 17, 2024
Study CompletionMay 26, 2024
TodayJul 2, 2026
Enrollment to primary: 9.5 yearsPosted 11.9 years ago
Interventions
Ice-Sense3TM/ ProSenseTMdevice